Krajina: Austrália
Jazyk: angličtina
Zdroj: Department of Health (Therapeutic Goods Administration)
fezolinetant, Quantity: 45 mg
Astellas Pharma Australia Pty Ltd
Tablet, film coated
Excipient Ingredients: mannitol; hyprolose; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; macrogol 8000; purified talc; iron oxide red
Oral
30 tablets, 100 tablets, 10 tablets (starter pack)
(S4) Prescription Only Medicine
VEOZA is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause (see section 5.1 Pharmacodynamic Properties ? Clinical Trials)
Visual Identification: Fezolinetant 45 mg tablets are round, light red, film coated tablets debossed with the Astellas logo and 645 on the same side; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 36 Months; Container Temperature: Store below 30 degrees Celsius
Registered